Study M182
Study name | Banasr M 2010 |
Title | Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole |
Overall design | This study investigates changes in glial function occurring in the rat prefrontal cortex (PFC) after chronic unpredictable stress (CUS), a rodent model of depression. Furthermore, we analyzed the effects of riluzole, a Food and Drug Administration-approved drug for the treatment of amyotrophic laterosclerosis, known to modulate glutamate release and facilate glutamate uptake, on CUS-induced glial dysfunction and depressive-like behaviors. Rats were divided into the following 4 groups (n = 8 in each group): (1) control group, (2) CUS group, (3) riluzole group (riluzole treatment at the dose of 4 mg/kg i.p), and (4) CUS + riluzole group (stressor plus riluzole treatment at the dose of 4 mg/kg i.p). Animals were first exposed to CUS for 15 days, and then were administered with riluzole daily for 21 days with continued CUS procedure. Plasma and cortical extracts were analyzed using 1H-NMR with or without 13C decoupling. |
Study Type | Type1; Type2; Type3; |
Data available | Unavailable |
Organism | Rat; Sprague-Dawley rat; |
Categories of depression | Animal model; Chronic mild stress model; Chronic mild stress model; Healthy individuals; Healthy individuals; Healthy individuals; |
Criteria for depression | Sucrose preference test, active avoidance test |
Sample size | 32 |
Tissue | Peripheral; Blood; Plasma; Central; Brain; Prefrontal cortex; |
Platform | NMR; NMR: Bruker AVANCE spectrometer (Bruker Instruments); |
PMID | |
DOI | |
Citation | Banasr M, Chowdhury GM, Terwilliger R, et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010;15(5):501-11. |
Metabolite |
